Treatment Information

Back

Prostate Cancer treatment details. Hormone.

Netherlands Cancer Institute, Amsterdam, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:5City/State/Province:Amsterdam
Treatments:HormoneHospital:Netherlands Cancer Institute
Drugs:Journal:Link
Date:Apr 2014

Description:

Patients:
This study involved 61 metastatic, castrate-resistant prostate cancer patients who previously received docetaxel and abiraterone acetate. The median patient age was 69 years.

Treatment:
Patients received hormone therapy with enzalutamide.

Toxicities:
There was one reported study-related death due to stroke. Grade 3 fatigue and musculoskeletal pain were also reported.

Results:
The median overall survival was 7.3 months.

Correspondence: Dr. Andries M. Bergman; email: [email protected]



Back